Capsules containing rice bran oil and fucoxanthin in patients with coronary heart disease
Phase 3
Recruiting
- Conditions
- Coronary artery disease.Atherosclerotic heart disease of native coronary arteryI25.1
- Registration Number
- IRCT20240717062445N1
- Lead Sponsor
- Rasht University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Age range 20 to 70 years
Not using vitamin and mineral supplements, antioxidants, fiber supplements, omega-3
No history of kidney disease, no current alcohol consumption
Coronary artery occlusion diagnosed by angiography by a cardiologist.
No current consumption of alcoholic beverages
Exclusion Criteria
Changes in the patient's coronary disease treatment plan during the study
Changing the type of drugs used, effective factors studied
Creating any kind of dissatisfaction in the field of oil taste and...
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link fucoxanthin and rice bran oil to lipid profile improvements in coronary artery disease (NCT062445N1)?
How does fucoxanthin supplementation compare to statins in reducing inflammatory markers like hs-CRP in I25.1 atherosclerotic heart disease patients (NCT062445N1)?
Which biomarkers, such as oxidized LDL or TNF-α, predict response to rice bran oil-fucoxanthin in coronary artery disease (NCT062445N1)?
What adverse events are reported with fucoxanthin and rice bran oil in cardiovascular trials, and how are they managed (NCT062445N1)?
Are there synergistic effects of combining fucoxanthin with PCSK9 inhibitors or omega-3 fatty acids in coronary heart disease (NCT062445N1)?